The intravitreal injection of drugs that inhibit vascular endothelial growth factor (anti-VEGF) is the first therapeutic option in the treatment of choroidal neovascularization that appears in age-related macular degeneration (AMD), as well as in the treatment of diabetic macular edema and macular edema secondary to retinal vein occlusion. This evidence concerns the gene VEGFA and macular retinal edema.